Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | STAT3 | P40763 | 2/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9065484 | 0.92 | KDM4E (0.48) | KDM4EALOX5STAT3NFE2L2PTGES | |
| SCHEMBL15568711 | 0.86 | ALOX5 (0.42) | KDM4EALOX5STAT3NFE2L2PTGES | |
| SCHEMBL1515768 | 0.85 | KDM4E (0.61) | KDM4EALOX5STAT3NFE2L2PTGES | |
| SCHEMBL13916239 | 0.84 | FDPS (0.41) | KDM4EALDH1A1FDPSSTK17BTDP1 | |
| SCHEMBL12648267 | 0.82 | FDPS (0.45) | ALOX5STAT3NFE2L2PTGESPTGS1 | |
| SCHEMBL12056204 | 0.80 | GRIN2D (0.41) | KDM4EALDH1A1FDPSTDP1GAA | |
| SCHEMBL12335690 | 0.79 | FDPS (0.53) | ALDH1A1FDPSTDP1GAAL3MBTL1 | |
| SCHEMBL10291447 | 0.79 | FDPS (0.53) | ALDH1A1FDPSTDP1GAAL3MBTL1 | |
| SCHEMBL18033266 | 0.79 | FDPS (0.45) | ALOX5STAT3NFE2L2PTGESPTGS1 | |
| SCHEMBL10497234 | 0.78 | FDPS (0.46) | KDM4EALDH1A1FDPSTDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110104055-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC. | 2011-05-05 | — | — | US | disclosed |
| US-20090060838-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC. | 2009-03-05 | — | — | US | disclosed |
| EP-0537742-B1 | Styrene derivatives | MITSUBISHI CHEM CORP (JP) | 1996-08-21 | — | — | EP | disclosed |
| US-5514711-A | ANTICARCINOGENIC AGENTS; SIDE EFFECT REDUCTION | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-05-07 | — | — | US | disclosed |
| EP-0537742-A2 | Styrene derivatives | Mitsubishi Chemical Corporation (JP) | 1993-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060838-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | IAPP, SNCA, BACE2 | KDM4E 3095/4885ALOX5 4378/4885STAT3 4217/4885 |
| US-20110104055-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | IAPP, SNCA, BACE2 | KDM4E 3429/4885ALOX5 4150/4885STAT3 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.